+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Acute Respiratory Distress Syndrome Market by Type, Cause, End-user - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 193 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 5967555
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Acute Respiratory Distress Syndrome Market grew from USD 2.56 billion in 2023 to USD 2.72 billion in 2024. It is expected to continue growing at a CAGR of 6.13%, reaching USD 3.89 billion by 2030.

Acute Respiratory Distress Syndrome (ARDS) is a severe inflammatory lung condition characterized by rapid onset of widespread inflammation in the lungs, leading to respiratory failure. It remains a critical focus within the healthcare sector due to its high mortality rate and frequent occurrence in intensive care units, necessitating ongoing medical intervention and innovation. ARDS cases have surged amid rising incidents of pneumonia, sepsis, and COVID-19, thus amplifying research and development within this domain. The application of ARDS market research spans across diagnostics, treatment regimens, and therapeutic devices like ventilators and extracorporeal membrane oxygenation (ECMO), with end-users primarily comprising hospitals, research institutions, and clinical laboratories. Market insights identify technological advancements in diagnostic precision, government funding for healthcare research, and increased awareness and education on critical care as key growth factors. The potential opportunities lie in developing novel therapeutics, personalizing ARDS treatment plans via AI and machine learning, and expanding the application of regenerative medicine strategies. Unfortunately, challenges persist, such as the high cost of advanced therapies, a shortage of skilled healthcare professionals, and the complexity of ARDS pathophysiology that hampers drug development. To mitigate these, businesses could focus on partnerships for drug development, invest in training programs for healthcare personnel, and enhance R&D funding. Areas ripe for innovation include nanomedicine for drug delivery, biomarker research for early diagnosis, and AI tools for predictive analytics to enhance treatment outcomes. The ARDS market remains dynamic, driven by a confluence of clinical requirements and technological advances, prompting stakeholders to constantly innovate to meet the evolving demands of patient care and enhance survival rates, all while addressing the systemic challenges that impede market expansion.

Understanding Market Dynamics in the Acute Respiratory Distress Syndrome Market

The Acute Respiratory Distress Syndrome Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Increasing prevalence of ARDS, partly due to rising rates of sepsis, trauma, and infections
    • Advancements in mechanical ventilation and supportive therapies
    • Rising focus on research and development of new pharmaceuticals
  • Market Restraints
    • High treatment costs and limited accessibility to advanced care
  • Market Opportunities
    • Ongoing development of personalized medicine approaches
    • Increasing government initiatives and healthcare infrastructure investments
  • Market Challenges
    • Regulatory complexities for the approval of new therapies and devices

Exploring Porter’s Five Forces for the Acute Respiratory Distress Syndrome Market

Porter’s Five Forces framework further strengthens the insights of the Acute Respiratory Distress Syndrome Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Acute Respiratory Distress Syndrome Market

External macro-environmental factors deeply influence the performance of the Acute Respiratory Distress Syndrome Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Acute Respiratory Distress Syndrome Market

The Acute Respiratory Distress Syndrome Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Acute Respiratory Distress Syndrome Market

The Acute Respiratory Distress Syndrome Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Acute Respiratory Distress Syndrome Market

The Acute Respiratory Distress Syndrome Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Acute Respiratory Distress Syndrome Market, highlighting leading vendors and their innovative profiles. These include APEPTICO GmbH, Armstrong Medical Ltd., Athersys, Inc., Bayer AG, Besmed Health Business Corp., Drägerwerk AG & Co. KGaA, EUROSETS S.R.L., F. Hoffmann-La Roche Ltd., Fisher & Paykel Healthcare Corporation Limited, GE HealthCare, Getinge AB, Hamilton Medical AG, HEALIOS K.K., LivaNova PLC, Novartis AG, NRx Pharmaceuticals, Pfizer Inc., Sun Pharmaceutical Industries Limited, Terumo Medical Corporation, United Therapeutics Corporation, and WEINMANN Emergency Medical Technology GmbH + Co. KG.

Market Segmentation & Coverage

This research report categorizes the Acute Respiratory Distress Syndrome Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Type
    • Diagnostics
    • Treatment
  • Cause
    • Direct Lung Injury
    • Indirect Lung Injury
  • End-user
    • Hospital
    • Speciality Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of ARDS, partly due to rising rates of sepsis, trauma, and infections
5.1.1.2. Advancements in mechanical ventilation and supportive therapies
5.1.1.3. Rising focus on research and development of new pharmaceuticals
5.1.2. Restraints
5.1.2.1. High treatment costs and limited accessibility to advanced care
5.1.3. Opportunities
5.1.3.1. Ongoing development of personalized medicine approaches
5.1.3.2. Increasing government initiatives and healthcare infrastructure investments
5.1.4. Challenges
5.1.4.1. Regulatory complexities for the approval of new therapies and devices
5.2. Market Segmentation Analysis
5.2.1. Type: Increasing need for diagnostics due to its potential for precision medicine application
5.2.2. End-user: Expanding preference for hospitals for management of ARDS
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Acute Respiratory Distress Syndrome Market, by Type
6.1. Introduction
6.2. Diagnostics
6.3. Treatment
7. Acute Respiratory Distress Syndrome Market, by Cause
7.1. Introduction
7.2. Direct Lung Injury
7.3. Indirect Lung Injury
8. Acute Respiratory Distress Syndrome Market, by End-user
8.1. Introduction
8.2. Hospital
8.3. Speciality Clinics
9. Americas Acute Respiratory Distress Syndrome Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Acute Respiratory Distress Syndrome Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Acute Respiratory Distress Syndrome Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.3.1. BioAegis scores USD 20millon BARDA contract to develop ARDS therapy
12.3.2. Veru Inc., Reaches Agreement With FDA on a New Phase III Clinical Trial for Sabizabulin for Broader Indication Hospitalized Adult Patients with any Type of Viral Acute Respiratory Distress Syndrome ARDS
12.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. ACUTE RESPIRATORY DISTRESS SYNDROME MARKET RESEARCH PROCESS
FIGURE 2. ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2023 VS 2030 (%)
FIGURE 9. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 11. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. AMERICAS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 13. AMERICAS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. UNITED STATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 15. UNITED STATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 21. ACUTE RESPIRATORY DISTRESS SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. ACUTE RESPIRATORY DISTRESS SYNDROME MARKET DYNAMICS
TABLE 7. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY DIRECT LUNG INJURY, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY INDIRECT LUNG INJURY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY SPECIALITY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. AMERICAS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 17. AMERICAS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
TABLE 18. AMERICAS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 19. AMERICAS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 20. ARGENTINA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 21. ARGENTINA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
TABLE 22. ARGENTINA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 23. BRAZIL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 24. BRAZIL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
TABLE 25. BRAZIL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 26. CANADA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 27. CANADA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
TABLE 28. CANADA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 29. MEXICO ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 30. MEXICO ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
TABLE 31. MEXICO ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 32. UNITED STATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 33. UNITED STATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
TABLE 34. UNITED STATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 35. UNITED STATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 36. ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 37. ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
TABLE 38. ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 39. ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 40. AUSTRALIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 41. AUSTRALIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
TABLE 42. AUSTRALIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 43. CHINA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 44. CHINA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
TABLE 45. CHINA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 46. INDIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 47. INDIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
TABLE 48. INDIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 49. INDONESIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 50. INDONESIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
TABLE 51. INDONESIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 52. JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 53. JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
TABLE 54. JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 55. MALAYSIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 56. MALAYSIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
TABLE 57. MALAYSIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 58. PHILIPPINES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 59. PHILIPPINES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
TABLE 60. PHILIPPINES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 61. SINGAPORE ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 62. SINGAPORE ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
TABLE 63. SINGAPORE ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 64. SOUTH KOREA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 65. SOUTH KOREA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
TABLE 66. SOUTH KOREA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 67. TAIWAN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 68. TAIWAN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
TABLE 69. TAIWAN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 70. THAILAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 71. THAILAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
TABLE 72. THAILAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 73. VIETNAM ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 74. VIETNAM ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
TABLE 75. VIETNAM ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 76. EUROPE, MIDDLE EAST & AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 77. EUROPE, MIDDLE EAST & AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 80. DENMARK ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 81. DENMARK ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
TABLE 82. DENMARK ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 83. EGYPT ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 84. EGYPT ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
TABLE 85. EGYPT ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 86. FINLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 87. FINLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
TABLE 88. FINLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 89. FRANCE ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 90. FRANCE ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
TABLE 91. FRANCE ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 92. GERMANY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 93. GERMANY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
TABLE 94. GERMANY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 95. ISRAEL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 96. ISRAEL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
TABLE 97. ISRAEL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 98. ITALY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 99. ITALY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
TABLE 100. ITALY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 101. NETHERLANDS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 102. NETHERLANDS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
TABLE 103. NETHERLANDS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 104. NIGERIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 105. NIGERIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
TABLE 106. NIGERIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 107. NORWAY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 108. NORWAY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
TABLE 109. NORWAY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 110. POLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 111. POLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
TABLE 112. POLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 113. QATAR ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 114. QATAR ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
TABLE 115. QATAR ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 116. RUSSIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 117. RUSSIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
TABLE 118. RUSSIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 119. SAUDI ARABIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 120. SAUDI ARABIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
TABLE 121. SAUDI ARABIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 122. SOUTH AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 123. SOUTH AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
TABLE 124. SOUTH AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 125. SPAIN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 126. SPAIN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
TABLE 127. SPAIN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 128. SWEDEN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 129. SWEDEN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
TABLE 130. SWEDEN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 131. SWITZERLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 132. SWITZERLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
TABLE 133. SWITZERLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 134. TURKEY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 135. TURKEY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
TABLE 136. TURKEY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 137. UNITED ARAB EMIRATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 138. UNITED ARAB EMIRATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
TABLE 139. UNITED ARAB EMIRATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 140. UNITED KINGDOM ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 141. UNITED KINGDOM ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
TABLE 142. UNITED KINGDOM ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 143. ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
TABLE 144. ACUTE RESPIRATORY DISTRESS SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Acute Respiratory Distress Syndrome Market, which are profiled in this report, include:
  • APEPTICO GmbH
  • Armstrong Medical Ltd.
  • Athersys, Inc.
  • Bayer AG
  • Besmed Health Business Corp.
  • Drägerwerk AG & Co. KGaA
  • EUROSETS S.R.L.
  • F. Hoffmann-La Roche Ltd.
  • Fisher & Paykel Healthcare Corporation Limited
  • GE HealthCare
  • Getinge AB
  • Hamilton Medical AG
  • HEALIOS K.K.
  • LivaNova PLC
  • Novartis AG
  • NRx Pharmaceuticals
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Limited
  • Terumo Medical Corporation
  • United Therapeutics Corporation
  • WEINMANN Emergency Medical Technology GmbH + Co. KG

Methodology

Loading
LOADING...

Table Information